Despite Fewer Known Risk Factors, Researchers Confirm Higher Risk of Cardiovascular Disease for Individuals with Celiac DiseaseFebruary 2nd 2023
Researchers found a 27% heightened risk of cardiovascular disease for individuals with celiac disease compared with those who didn’t have the condition.
Phase 3 Trial of Ciltacabtagene Autoleucel Meets Primary Endpoint in Relapsed, Refractory Multiple MyelomaFebruary 2nd 2023
The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.
Pembrolizumab Plus Chemotherapy Significantly Improves Overall Survival in First-Line Advanced, Unresectable Biliary Tract CancerJanuary 26th 2023
Specific data and results for pembrolizumab in patients with advanced or unresectable biliary tract cancer will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
Trial Results Demonstrate Significant Overall Survival With Zanidatamab in AdenocarcinomaJanuary 25th 2023
In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.